$SNSS #Sunesis Pharmaceuticals Sunesis Pharmaceuticals - Vecabrutinib not to progress, SNS-510 elevated: Sunesis announced on 23 June that it would not be advancing vecabrutinib to the Phase II portion of its Phase Ib/II study following… https://t.co/2H0p469Mav #equity #stocks https://t.co/Q1VX23UtLs